TENAYA THERAPEUTICS, INC.

(TNYA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

27,324,727 Common Stock of Tenaya Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022.

01/26/2022 EDT

27,324,727 Common Stock of Tenaya Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022. These Common Stock will be under lockup for 181 days starting from 29-JUL-2021 to 26-JAN-2022. Details: The directors and officers, and substantially all securityholders have agreed that, without the prior written consent of Morgan Stanley & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co. on behalf of the underwriters, will not, and will not publicly disclose an intention to, during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the Restricted Period): offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock.


© S&P Capital IQ 2022
All news about TENAYA THERAPEUTICS, INC.
05/20Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European S..
BU
05/17Morgan Stanley Lowers Tenaya Therapeutics' Price Target to $15 From $19, Maintains Over..
MT
05/12Tenaya Therapeutics Q1 Net Loss Narrows
MT
05/11TENAYA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/11Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/11Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business ..
BU
05/03Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform C..
BU
04/28Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at ..
BU
04/28Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at ..
CI
03/24Tenaya Therapeutics to Participate in Upcoming Investor Conferences
BU
More news
Analyst Recommendations on TENAYA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -138 M - -
Net cash 2022 90,4 M - -
P/E ratio 2022 -2,00x
Yield 2022 -
Capitalization 275 M 275 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 125
Free-Float 93,7%
Chart TENAYA THERAPEUTICS, INC.
Duration : Period :
Tenaya Therapeutics, Inc. Technical Analysis Chart | TNYA | US87990A1060 | MarketScreener
Technical analysis trends TENAYA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,65 $
Average target price 30,33 $
Spread / Average Target 356%
EPS Revisions
Managers and Directors
Faraz Ali Chief Executive Officer, Secretary & Director
Leone D. Patterson Chief Financial & Business Officer
David V. Goeddel Chairman
Timothy Hoey Chief Scientific Officer
Whittemore Tingley Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TENAYA THERAPEUTICS, INC.-64.91%275
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567